Filing Flows › Voyager Therapeutics (VYGR) › Q1 2025
Voyager Therapeutics (VYGR) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Voyager Therapeutics (VYGR) reported revenue of $6.5M for the first quarter 2025 (Q1 2025), -67% from a year earlier and +3% from the quarter before. Operating margin was -536.0%, net loss $31.0M (479.2% of revenue).
Voyager Therapeutics, Q1 2025: revenue $6.5M (-67% year over year), operating margin -536.0%, net loss $31.0M, operating cash flow −$37.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.5M | +3% | -67% |
| Operating profit | −$34.7M | — | — |
| Net earnings | −$31.0M | — | — |
| Operating cash flow | −$37.9M | — | — |
What changed
Revenue was $6.5M in Q1 2025, down 67% year over year and up 3% from the previous quarter.
Operating costs exceeded revenue by $34.7M, an operating margin of -536.0%. Total costs grew 15% against a revenue fall of 67%. The fastest-growing cost line was Research & development (+16%). The quarter ended with a net loss of $31.0M, narrower than the previous quarter's $34.5M loss.
Operating cash flow was −$37.9M. Non-cash charges added back $1.0M of depreciation and $3.7M of share-based compensation. Working capital and other items used $11.6M. Capital expenditures of $658K exceeded it, leaving free cash flow of −$38.6M.
Questions
What was Voyager Therapeutics' revenue in the first quarter 2025?
Voyager Therapeutics (VYGR) reported revenue of $6.5M for the first quarter 2025 (Q1 2025), -67% from a year earlier and +3% from the quarter before.
Was Voyager Therapeutics profitable in the first quarter 2025?
Operating loss was $34.7M (-536.0% of revenue) and net loss $31.0M.